

# **An emergency system for monitoring pulse oximetry, peak expiratory flow and body temperature of patients with COVID-19 at home: Development and preliminary application**

Leonardo Pereira Motta<sup>1</sup>, Pedro Paulo Ferreira da Silva<sup>1</sup>, Bruno Max Borguezan<sup>2</sup>, Jorge Luis Machado do Amaral<sup>3</sup>, Lucimar Gonçalves Milagres<sup>2</sup>, Márcio Neves Bóia<sup>2</sup>, Marcos Rochedo Ferraz<sup>1</sup>, Roberto Mogami<sup>2</sup>, Rodolfo Acatauassú Nunes<sup>2</sup>, Pedro Lopes de Melo<sup>1,\*</sup>

<sup>1</sup> Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil

<sup>2</sup> Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil

<sup>3</sup> Department of Electronics and Telecommunications Engineering, State University of Rio de Janeiro, Rio de Janeiro, Brazil

\* Corresponding author

E-mail: [plopes@uerj.br](mailto:plopes@uerj.br) (PLM)

The authors contributed equally to this work.

**Short Title:** An emergency system for monitoring COVID-19 at home.

1 **Abstract**

2

3 **Background**

4 COVID-19 is characterized by a rapid change in the patient's condition, with major  
5 changes occurring over a few days. Our aim was to develop and evaluate an emergency  
6 system for monitoring patients with COVID-19, which may be useful in hospitals where  
7 more severe patients stay in their homes.

8 **Methodology/Principal findings**

9 The system consists of the home-based patient unit, which is set up around the patient  
10 and the hospital unit, which enables the medical staff to telemonitor the patient's  
11 condition and help to send medical recommendations. The home unit allows the data  
12 transmission from the patient to the hospital, which is performed using a cell phone  
13 application. The hospital unit includes a virtual instrument developed in LabVIEW®  
14 environment that is able to provide a real-time monitoring of the oxygen saturation  
15 (SpO<sub>2</sub>), beats per minute (BPM), body temperature (BT) and peak expiratory flow (PEF).  
16 Abnormal events may be fast and automatically identified. After the design details are  
17 described, the system is validated by a 30-day home monitoring study in 12 controls and  
18 12 patients with COVID-19 presenting asymptomatic to mild disease. Patients presented  
19 reduced SpO<sub>2</sub> (p<0.0001) and increased BPM values (p<0.0001). Three patients (25%)  
20 presented PEF values between 50 and 80% of the predicted. Three of the 12 monitored  
21 patients presented events of desaturation (SpO<sub>2</sub><92%). The experimental results were in  
22 close agreement with the involved pathophysiology, providing clear evidences that the  
23 proposed system can be a useful tool for the remote monitoring of patients with COVID-  
24 19.

25 **Conclusions**

26 An emergency system for home monitoring of patients with COVID-19 was developed  
27 in the current study. The proposed system allowed us to quickly respond to early  
28 abnormalities in these patients. This system may contribute to conserve hospital resources  
29 for those most in need, while simultaneously enabling early recognition of patients under  
30 acute deterioration, requiring urgent assessment.

31

32

33

## 34 **1. Introduction**

35

36 We are experiencing a global pandemic due to COVID-19 of devastating consequences.  
37 The highly infectious pathogen that causes COVID-19, SARS-CoV-2, has infected most  
38 of the countries in the world, with over 62.7 million confirmed cases, and just under  
39 1.460.000 deaths as of December 1, 2020 [1].

40 As the hospital environment becomes more crowded, the criteria for hospital  
41 admission become progressively stricter and, as a consequence, more severe patients stay  
42 in their homes awaiting improvement or worsening. It was pointed out previously that a  
43 rapid clinical deterioration may occur in the initial phase of COVID-19, due to the  
44 development of arterial hypoxemia without a concomitant increase in work of breathing  
45 [2]. This can prevent an adequate perception by the patient of the real magnitude of the  
46 problem. In this context, patients have emerged who silently and rapidly decompensate  
47 respiratory function at home, progressing to death even before receiving specialized care.  
48 Thus, it is essential to obtain severity markers, especially to predict and prevent the  
49 evolution to hospitalization in ICU and death. In this emergency scenario, a consensus  
50 has emerged in the literature on the need to institute home monitoring of these patients  
51 [3-5], enabling early identification of those who deteriorate acutely and require urgent  
52 assessment.

53 In this context, our aim was to develop an emergency system for monitoring  
54 patients with COVID-19, which may be useful in hospitals where more severe patients  
55 stay in their homes. We hypothesized that an emergency system based on a smart phone  
56 application and specific instruments that allows oxygen saturation, body temperature and  
57 peak expiratory flow could be useful as a COVID-19 home-monitoring tool in clinical  
58 practice.

## 59 **2. Proposed emergency home monitoring system**

60 Based on previous studies monitoring respiratory diseases [6] and the specific  
61 characteristics of COVID-19 [7, 8], the following variables were selected for monitoring:

62

### 63 **2.1. Pulse Oximetry**

64 In the particular case of COVID-19, this monitoring is essential because in about 10% of  
65 cases, especially in the elderly and people with comorbidities, hypoxemia can develop  
66 quickly, implying intensive therapy with mechanical ventilation. It is also recognized that  
67 hypoxemia is at the very heart of the most severe cases of COVID-19 [9]. In addition,  
68 there is now fairly strong evidence that the mortality risk increased with the oxygen  
69 saturation reduction [10], which highlights the importance of continuous monitoring of  
70 this parameter.

71

### 72 **2.2. Body temperature**

73 It is known that increased body temperature (BT) is a marker of infection, so temperature  
74 provides important orientation of health professionals during the COVID 19 disease  
75 course [11]. A recent report by the World Health Organization showed that of the  
76 approximately 56,000 laboratory confirmed cases studied in China, among the typical  
77 signs and symptoms of COVID-19, increased BT is the most common [12]. Thus, BT is  
78 widely recognized in the literature as an important measurement in the COVID-19  
79 pandemic [11-13], that can be used as an easily obtained prognostic indicator [11, 14].

80

### 81 **2.3. Peak expiratory flow**

82 The monitoring of peak expiratory flow (PEF) is widely recommended in international  
83 guidelines for the management of asthma. In these patients, the predicted percentage of

84 PEF correlates reasonably well with the predicted percentage for forced expiratory  
85 volume in the first second (FEV1) and provides an objective measure of airflow limitation  
86 when spirometry is not available [15]. The value of PFE can be measured using portable  
87 meters, which are affordable and relatively simple to handle. This method is widely  
88 recognized as suitable for monitoring the progression of the disease and its treatment,  
89 using the initial values obtained from the patient as a control [16-18]. The monitoring of  
90 PEF also helps to monitor the improvement in the patient after a particular mode of  
91 treatment [18]. In general, PEF is reduced in all types of respiratory diseases. PEF has  
92 also been a valuable measure in differentiating dyspnea secondary to congestive heart  
93 failure versus chronic lung disease [39]. Ignacio-garcia et al. observed a significant  
94 improvement in morbidity parameters in the 35 patients with asthma monitored through  
95 peak flow at home [19].

96 In asthma, the drop in PEF values indicates a decrease in the condition of patients.  
97 From the initial measurements of PEF, the fall in its value by up to 20% indicates caution,  
98 but there is no danger, as this variation is not unexpected in a 24-hour period. A drop of  
99 20 to 50% indicates that the patient is at risk of suffering an exacerbation. If the drop  
100 exceeds 50%, patients are at imminent risk of exacerbation. Reduced PEF values in  
101 patients with asthma precede the presence of shortness of breath or even the signs of  
102 wheezing and snoring detected by the stethoscope. Thus, correct knowledge of PEF  
103 predicts the patient's condition and offers valuable time and opportunity to take all  
104 necessary measures to prevent adverse effects of the disease. The integration of PEF  
105 monitoring would allow the identification of fall limits of the PEF suitable for monitoring  
106 the COVID-19, reducing hospitalizations and death. In this sense, previous studies show  
107 that the daily monitoring of PEF was a useful tool in the identification of patients with  
108 COPD predisposed to worse clinical outcomes [20].

109 Previous studies describing the physiological changes in COVID-19 have shown  
110 rapid reductions in lung volumes in the presence of edema [8, 21], which highlights the  
111 importance of monitoring the PEF of these patients. However, there is no previous studies  
112 concerning the use of PEF in COVID-19.

113

#### 114 **2.4. System architecture**

115 The general architecture of the system is reported in Figure 1. The system consists mainly  
116 of two parts: 1) the home-based patient unit, which is set up around the patient to acquire  
117 data and to receive medical recommendations, and 2) the hospital unit, which enables the  
118 medical staff to telemonitor the patient's condition and help to send medical  
119 recommendations.

120

121  Insert Figure 1

122

123 Considering the urgency of patient care, the home-based patient unit was  
124 developed using readily available commercial instruments. In order to simplify the use of  
125 the system by patients, easy-to-use instruments were selected. Thus, patients were  
126 assessed using a portable pulse oximeter (finger type, BIC model YK-80A) together with  
127 a disposable peak flow meter (Medicate, model 72000M). The used thermometer was the  
128 one owned by the patients.

129 The home unit allows the data transmission from the patient to the hospital, which  
130 is performed using a cell phone application. The application was developed in Java using  
131 the integrated development environment Android Studio (version 3.6.3). It is based on a  
132 form that is filled out and sent by the patient. To make clinical use easier for non-technical

133 personnel, a dedicated user-friendly front panel was developed in the smartphone  
134 environment. This interface is shown in Figure 2.

135

136 

137

138 After filled out, this form is sent from the application to an online script from  
139 Google, the script saves the data in a worksheet according to the patient ID. To this end,  
140 the application uses Google Sheets (spreadsheet where data is saved) and Google Scrips  
141 (script that integrates the application and Google Spreadsheet). As a result, the application  
142 creates an Excel file with one spreadsheet for each patient, which the maximum size is 5  
143 million cells.

144 Additionally, the values obtained in these exams are also recorded by the patients  
145 in a follow-up paper personal diary. These diaries are provided to patients at the beginning  
146 of the monitoring. This redundancy is important in order to maintain the perfect  
147 functioning of the system even in case of failures in the Internet or other system  
148 component.

149 In the hospital environment, on the other hand, the hardware platform was  
150 constituted by an Intel Core i7-8750H, 2.2 GHz computer with 16 GB of RAM, a hard  
151 disk of 1 TB and Microsoft Windows 10 operating system. The software was developed  
152 in the LABVIEW 2020 environment (National Instruments, Austin, TX). A user-friendly  
153 front panel was also developed to be used in the hospital environment. This interface is  
154 shown in Figure 3. Its use is described in the flow diagram presented in Figure 4, and the  
155 basic LabVIEW program is described in Figure 5.

156

157 

158

159

Insert Figure 4

160

161

Insert Figure 5

162

163

164

165

166

167

168

The application installed on patients' cell phones sends the data obtained over the monitoring periods to the analysis center in the hospital, where they are stored. Initially, the program (Figure 5) reads the data of the first patient and elaborates the graphs of SpO<sub>2</sub>, BPM, temperature and PEF (Figure 4). This provides a graphical description of these readings against time (Figure 3), allowing the user to detect trends toward normality or abnormal changes in the mentioned parameters by visual analysis.

169

170

171

172

173

174

The program allows the user to select the minimum SpO<sub>2</sub> value considered appropriate. Previous studies used a minimum normal SpO<sub>2</sub> of 92% [22, 23], while others report that these values are between 93% and 94% [10]. The program automatically searches for the minimum SpO<sub>2</sub> values presented by this patient and compared with the selected value. In the presence of saturation values smaller than the value selected by the user, a red indicator light starts flashing, simultaneously with an alarm beep.

175

176

177

178

179

180

181

182

Similar analyses are performed in terms of BPM and temperature. The user can select the maximum BPM value considered appropriate, as well as the maximum temperature considered normal. In this sense, usually values above 100 BPM are indicative of tachycardia [24] and body temperatures above 37 °C are considered abnormal [11, 24]. The system automatically identifies abnormal values presented by this patient and, in the presence of these events, specific red light indicators starts flashing, indicating the nature of the abnormal event, simultaneously with an alarm sound, similar to the indication of abnormal values in SpO<sub>2</sub>.

183           EPF analyses are performed taking into account the measured absolute values  
184 (blue trace in the EPF chart in Figure 9) and the percent of the predicted values [25] for  
185 each monitored patient (yellow trace in the EPF chart in Figure 9). We are performing an  
186 initial analysis adapting a methodology traditionally used in asthmatic patients [26]. A  
187 zone scheme similar to a traffic light system (green-yellow-red zones) was used to  
188 evaluate the predicted EPF values (EPFp) obtained by the patient. The green zone is  
189 characterized by PEF readings between 100 to 80% of the EPFp, and signals "all clear".  
190 The yellow zone includes reading from 80 to 50% of the EPFp, and signals "caution",  
191 while the red zone (below 50% of the EPFp) signals "medical alert". The limits used in  
192 the cited zones are probably not adequate for COVID-19 patients, and we hope that they  
193 can be rapidly adjusted as the experience of using the system accumulates.

194           When the system is started and used for the first time on the day, the cited analyses  
195 are performed for all patients under home monitoring (Figure 4). To simplify the visual  
196 analysis of the results from nontechnical personnel, the software allows the user to  
197 perform this first evaluations with an automatic increment among patients and a constant  
198 time window for each patient (2 minutes, for example, Figure 3). The automatic increment  
199 process can be interrupted if more intriguing results that require a longer analysis time  
200 are observed in a given patient. The patient details, monitoring values, and the cited  
201 analysis may be saved for further analysis (Figure 4).

202           After the first scan of patient results, the system automatically updates the results  
203 whenever a patient reports new measurements (Figure 4). This is an important feature as  
204 it allows the real-time identification of adverse events, and, as a consequence, the  
205 clinician may quickly implement the treatment plan. This can be very useful in COVID-  
206 19, since this disease is characterized by the presence of rapid deterioration in the patient  
207 conditions.

208           The system also allows the analysis of the results of the measurements in the  
209 measurements performed in patients in an asynchronous manner, while monitoring is  
210 performed. The medical recommendations, obtained from the analysis of the results sent  
211 previously, may be sent using e-mail messages. In case of severely abnormal values,  
212 emergency cell phone contact may be used. To help this contact, the system also  
213 automatically makes available the patient's phone number. To receive recommendations  
214 in this manner could be a significant benefit for the patient, allowing the fast and easy  
215 adjustment of medical treatments. The front panel of this program is similar to that used  
216 in the online monitoring system. The interested reader may find a detailed description of  
217 this front panel in the supplement (Figure S1).

218           All the programs used in the current study are available from the corresponding  
219 author on request.

220

## 221 **Methods**

222

223           The Research Ethics Committee of the Pedro Ernesto University Hospital (HUPE)  
224 approved the study that obeys the Declaration of Helsinki. The written post-informed  
225 consent of all volunteers was obtained before inclusion in the study.

226

### 227 **Monitoring protocol**

228           Based on previous studies on asthma, patients are asked to measure and record their  
229 SpO<sub>2</sub>, BPM, body temperature and PEF two times daily, in the morning and in the  
230 afternoon, for thirty days. All of the instruments were provided at no cost to the patients.

231

232

## 233 **Preliminary study**

234 Twenty-four volunteers were selected for the study, including 12 controls and 12  
235 diagnosed with COVID-19. The control group was composed of healthy subjects with no  
236 history of COVID-19, tobacco use, as well as cardiac or pulmonary disease. Among  
237 COVID-19 patients, all presented asymptomatic to mild disease. All patients were older  
238 than 18 years of age, and were enrolled if they had positive COVID-19 testing, which  
239 was performed using reverse transcriptase–polymerase chain reaction (RT-PCR) of an  
240 oropharyngeal or nasopharyngeal swab. Hospital evaluations after RT-PCR tests showed  
241 that all patients had resting  $SpO_2 \geq 94\%$  before the home-monitoring period. In the  
242 presence of values indicating adverse events during this period, the need for  
243 hospitalization was left to the discretion of the physician evaluating the patient,  
244 independent of this study. None of the studied patients required noninvasive or invasive  
245 ventilation during or after the monitoring period.

246

## 247 **Statistics**

248

249 Initially, the sample distribution characteristics were assessed using Shapiro-Wilk's  
250 test. Since data were non-normally distributed, non-parametric analysis (Mann-Whitney  
251 test) were performed. Differences with  $p \leq 0.05$  were considered statistically significant.  
252 These analyses were performed using Origin® 8.0 (Microcal Software Inc.,  
253 Northampton, Massachusetts, United States). Graphs were elaborated using MedCalc  
254 13.1, and the results are present as the median and interquartile range.

255

256

## 257 **Preliminary results**

258

259 The biometric characteristics of the studied subjects are described in Table 1,  
260 while the past medical history and medication use of the patients with COVID-19 are  
261 described in Table 2.

262

263 Table 1: Mean  $\pm$  SD of the biometric characteristics of control individuals and patients  
264 with COVID-19.

	Age (years)	Body mass (kg)	Height (cm)	BMI (kg/m <sup>2</sup> )	Gender (M/F)
Control (n=12)	38.2 $\pm$ 15.0	68.2 $\pm$ 10.7	167.8 $\pm$ 7.2	24.2 $\pm$ 3.1	4/8
COVID-19 (n= 12)	37.2 $\pm$ 13.3	77.6 $\pm$ 16.4	163.8 $\pm$ 8.2	28.9 $\pm$ 5.4	3/9
p	ns	ns	ns	0.02	-

265

266 Table 2: Characteristics of COVID-19 patients.

	N	(%)
Smoking	1	8.3
Overweight	7	58.3
Obesity	3	25.0
Controlled diabetes	1	8.3
Pre-diabetes	1	8.3
Hypertension	2	16.7
Epilepsy	1	8.3

---

Cardiac arrhythmias	1	8.3
Essential thrombocytosis	1	8.3
Received hydroxychloroquine and azithromycin	5	41.2
Ivermectin	3	25.0

---

267 Overweight was defined as body mass index (BMI) between 25 and 30 kg/m<sup>2</sup>; Obesity  
268 was defined as BMI ≥ 30 kg/m<sup>2</sup>; N, number of patients; %: percentage of the total  
269 number of patients.  
270

271 Figures 6 and 7 describes the results of the SpO<sub>2</sub> and BPM in controls and patients,  
272 respectively.

273

274 

275

276 

277

278 COVID-19 resulted in a significant reduction in SpO<sub>2</sub> (Figure 8A, p<0.0001) and  
279 increased values of BPM (Figure 8B, p<0.0001).

280

281 

282

283 Figure 9 shows the results obtained in the daily monitoring of temperature and  
284 PEF in patients with COVID-19 during 30 days. Most of the studied patients presented  
285 PEF values above 80% during the monitoring period (8 patients, 66.7%), while 3 patients  
286 (25%) had values between 50 and 80% of predicted (Figure 9). Two of the 12 patients  
287 (17%) showed transient values below 50%, which subsequently evolved to values  
288 between 50 and 80% of the predicted values.

289

290 Insert Figure 9

291

## 292 Discussion

293 To the best of our knowledge, this is the first study to provide a detailed description  
294 of an emergency remote monitoring system for individuals with COVID-19. The system  
295 is able to provide a real-time monitoring of oximetry, BPM, body temperature and peak  
296 expiratory flow. The preliminary results obtained in the 30-day validation study showed  
297 that patients with COVID-19 presented reduced SpO<sub>2</sub> and PEF values, as well as  
298 increased BPM values. This was also the first study to investigate the use of PEF in  
299 COVID-19. The proposed system allowed us to quickly respond to early abnormalities in  
300 patients with COVID-19.

301 During the 30-days period of the initial tests of the proposed system, 720 data-points  
302 regarding SpO<sub>2</sub> were remotely obtained, resulting in a total of 16 alerts among the 12  
303 monitored patients (Figure 6). It was observed that these alerts resulted from an abrupt  
304 drop in SpO<sub>2</sub> rather than a gradual decline. This is consistent with previous results [23],  
305 and is probably associated with the rapid deterioration caused by a surge in  
306 proinflammatory molecules in the “cytokine storm” phase of COVID-19 [27].

307 The values of SpO<sub>2</sub> were reduced in patients with COVID-19 in comparison with  
308 controls (Figure 8A). This finding is consistent with the observation that in the initial  
309 phase of COVID-19 there is an increase in V/Q mismatch and thus persistence of  
310 pulmonary arterial blood flow to non-ventilated alveoli. The current understanding is that  
311 this results from the infection, which leads to a modest local interstitial edema and loss  
312 of surfactant. These factors are associated with alveolar collapse and intrapulmonary  
313 shunting [2]. The results observed in Figure 6 are in line with that obtained by O’Carroll

314 and collaborators [28] investigating the remote monitoring of SpO<sub>2</sub> in individuals with  
315 COVID-19.

316 It was pointed out previously that data are lacking for young adults who often  
317 present with mild or asymptomatic disease, a part of the population considered to be  
318 highly contagious [29]. Figures 7 and 8B contributes to elucidate this question providing  
319 evidence that COVID-19 introduces increased values of BPM in comparison with control  
320 subjects (Figure 8B). These results are consistent with a previous review showing that  
321 COVID-19 is related with a number of cardiovascular complications [30], and the use of  
322 increased heart rate as a clinical criteria for hospital admission in COVID-19 pneumonia  
323 [31].

324 It is known that the degree of temperature elevation might reflect the severity of  
325 inflammation [11]. Previous studies suggest that poor BT control during the COVID 19  
326 disease course is a marker of poor prognosis and BT can be used as an easily obtained  
327 prognostic indicator [11]. At this point in the COVID-19 outbreak, however, a specific  
328 fever pattern associated with this disease has not yet been identified. In fact, there is a  
329 paucity of data on temperature management for COVID-19 [14]. The results of the  
330 present study (Figures 9A and B) indicate that the proposed system can help to fill this  
331 important gap in the literature. Low fever events were observed in 5 of the 12 studied  
332 patients (41.7%), which is consistent with the characteristics of asymptomatic to mild  
333 disease of the studied COVID-19 group.

334 Figure 9C and D shows that most of the studied patients presented normal PEF  
335 values during the monitoring period. Patients who have been infected by the Coronavirus  
336 may develop pulmonary edema and atelectasis, which may result in a reduction in lung  
337 volume. Thus, it may be speculated that this reduction may introduce a limitation of the  
338 expiratory flow influencing the values obtained in peak-flow measurements. This

339 processes would be similar to that observed in restrictive diseases in which the volumes  
340 exhaled are reduced [32]. These effects may explain, at least in part, the decrease in PEF  
341 presented in three of the studied patients, as well as the transient values below 50% of the  
342 predicted values observed in two patients, as described in Figure 9A. It is noteworthy that  
343 one of the patients who had EPF <50% also had desaturation <92%.

344 There is general agreement in the literature that, given the severity of the ongoing  
345 global pandemic, the ability to remotely monitor patients who do not require  
346 hospitalization is essential for optimal utilization of health care resources [23]. To  
347 contribute in this direction, this study presents a low-cost open-architecture emergency  
348 system for remote monitoring of patients with COVID-19. There are currently no data to  
349 guide the use of home pulse oximetry in COVID-19 patients or its validity in identifying  
350 disease progression [23]. There is also a paucity of data on temperature management for  
351 COVID-19. No previous study has investigated the use of EFP in COVID-19. The system  
352 presented in this study may help to quickly accumulate data on SpO<sub>2</sub>, body temperature  
353 and EPF, contributing to the development of the guidelines for these clinical practices.

354 Remote monitoring systems has been increasingly used in respiratory diseases [6,  
355 33-36]. An important factor, in the particular case of COVID-19, is that the disease is  
356 characterized by a rapid change in the patient's condition, with major changes occurring  
357 over a few days. The proposed system may provide an early detection of patient's  
358 conditions deteriorating at home. The use of this technology allowed us to facilitate  
359 discharge in patients with mild-to-moderate disease in a safe and appropriate manner.  
360 This procedure hold the potential to increase bed availability without compromising safe  
361 patient care.

362 We acknowledge the limitations of our study, including unknown methods of  
363 temperature measurement. Nevertheless, a clear trend in increased mortality among the

364 patients with poor temperature control highlights the usefulness of this noninvasively and  
365 easily obtained parameter for evaluating patients' prognoses.

366 Secondly, one could argue that the study presents a small sample size, and  
367 additional studies, including a more significant number of subjects are necessary. These  
368 studies would allowed us to perform a detailed investigation concerning the utilization of  
369 home pulse oximetry, body temperature and peak expiratory flow monitoring to identify  
370 robust predictors of hospitalization.

371 Finally, the system validation was performed in subjects from a Brazilian  
372 population at a single practice site, which affects the study's generalizability. Therefore,  
373 multicenter studies are necessary in the future to expand the generalizability of these  
374 findings. The study used broad inclusion criteria and was performed in a typical setting  
375 under usual clinical procedures, which enhanced its generalizability.

376

## 377 **Conclusion**

378 An emergency system for home monitoring of SpO<sub>2</sub>, body temperature and PEF in  
379 patients with COVID-19 was developed in the current study. This was the first study to  
380 propose such a system and to evaluate the use of PEF in COVID-19. Using this system,  
381 the acquisition and analysis of the cited signals can be performed remotely through the  
382 Internet. The ability of the system to detect abnormal events was initially validated by a  
383 30-day monitoring study in normal subjects and patients with COVID-19. In close  
384 agreement with previous results and physiological fundamentals, the presence of COVID-  
385 19 resulted in reduced values of SpO<sub>2</sub>, increased BPM, fever events in 41.7% of the  
386 patients and decreased PEF in 33% of the studied patients.

387           The proposed system may contribute to conserve hospital resources for those most  
388 in need, while simultaneously enabling early recognition of patients under acute  
389 deterioration, requiring urgent assessment.

390           Based on these promising results, future work includes a clinical trial in which we  
391 will perform a follow up in well-defined groups of patients with COVID-19. This will  
392 provide a detailed evaluation of the clinical contribution of the home monitoring approach  
393 in improving the patient's care and outcomes.

394

## 395 **REFERENCES**

396

- 397 1. WHO Coronavirus Disease (COVID-19) Dashboard 2020 [cited 2020 11/04/2020].  
398 Available from: <https://covid19.who.int/>.
- 399 2. Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The  
400 pathophysiology of 'happy' hypoxemia in COVID-19. *Respiratory research*.  
401 2020;21(1):198. doi: 10.1186/s12931-020-01462-5. PubMed PMID: 32723327;  
402 PubMed Central PMCID: PMC7385717.
- 403 3. Portnoy J, Waller M, Elliott T. Telemedicine in the Era of COVID-19. *The journal*  
404 *of allergy and clinical immunology In practice*. 2020. doi:  
405 10.1016/j.jaip.2020.03.008. PubMed PMID: 32220575; PubMed Central PMCID:  
406 PMC7104202.
- 407 4. Bashshur R, Doarn CR, Frenk JM, Kvedar JC, Woolliscroft JO. Telemedicine and  
408 the COVID-19 Pandemic, Lessons for the Future. *Telemedicine journal and e-health*  
409 *: the official journal of the American Telemedicine Association*. 2020. doi:  
410 10.1089/tmj.2020.29040.rb. PubMed PMID: 32275485.
- 411 5. Nakshbandi G, Moor CC, Wijzenbeek MS. Home monitoring for patients with ILD  
412 and the COVID-19 pandemic. *The Lancet Respiratory medicine*. 2020. doi:  
413 10.1016/S2213-2600(20)30452-5. PubMed PMID: 33075296; PubMed Central  
414 PMCID: PMC7567485.
- 415 6. Pare G, Jaana M, Sicotte C. Systematic review of home telemonitoring for chronic  
416 diseases: the evidence base. *Journal of the American Medical Informatics*  
417 *Association : JAMIA*. 2007;14(3):269-77. doi: 10.1197/jamia.M2270. PubMed  
418 PMID: 17329725; PubMed Central PMCID: PMC2244878.
- 419 7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients  
420 infected with 2019 novel coronavirus in Wuhan, China. *Lancet*.  
421 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. PubMed PMID:  
422 31986264.
- 423 8. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. *Jama*. 2020.  
424 doi: 10.1001/jama.2020.6825. PubMed PMID: 32329799.
- 425 9. Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia Is Baffling to  
426 Physicians. *American journal of respiratory and critical care medicine*.

- 427 2020;202(3):356-60. doi: 10.1164/rccm.202006-2157CP. PubMed PMID:  
428 32539537; PubMed Central PMCID: PMC7397783.
- 429 10. Torjesen I. Covid-19: Patients to use pulse oximetry at home to spot deterioration.  
430 *Bmj*. 2020. Epub 27 October 2020. doi: 10.1136/bmj.m4151.
- 431 11. Tharakan S, Nomoto K, Miyashita S, Ishikawa K. Body temperature correlates with  
432 mortality in COVID-19 patients. *Critical care*. 2020;24(1):298. doi: 10.1186/s13054-  
433 020-03045-8. PubMed PMID: 32503659; PubMed Central PMCID: PMC7274509.
- 434 12. W.H.O. Report of the WHO-China Joint Mission on Coronavirus Disease 2019  
435 (COVID-19)2020.
- 436 13. Hsiao SH, Chen TC, Chien HC, Yang CJ, Chen YH. Measurement of body  
437 temperature to prevent pandemic COVID-19 in hospitals in Taiwan: repeated  
438 measurement is necessary. *The Journal of hospital infection*. 2020;105(2):360-1. doi:  
439 10.1016/j.jhin.2020.04.004. PubMed PMID: 32278704; PubMed Central PMCID:  
440 PMC7195063.
- 441 14. Drewry AM, Hotchkiss R, Kulstad E. Response to "Body temperature correlates with  
442 mortality in COVID-19 patients". *Critical care*. 2020;24(1):460. doi:  
443 10.1186/s13054-020-03186-w. PubMed PMID: 32709253; PubMed Central  
444 PMCID: PMC7380658.
- 445 15. World Health Organization WHO. GINA – Global Initiative for Asthma2020 04-07-  
446 2015.
- 447 16. Shingo S, Zhang J, Reiss TF. Correlation of airway obstruction and patient-reported  
448 endpoints in clinical studies. *The European respiratory journal*. 2001;17(2):220-4.  
449 doi: 10.1183/09031936.01.17202200. PubMed PMID: 11334123.
- 450 17. Goldberg S., Springer C, Avital A, Godfrey S, Bar-Yishay E. Can peak expiratory  
451 flow measurements estimate small airway function in asthmatic children? *CHEST*.  
452 2001;120(2):482-8.
- 453 18. Lenfant C., AL. S. Objective measures of lung function. *J ALLERGY CLIN*  
454 *IMMUNOL*. 1991;88(3(2)):439-46.
- 455 19. Ignacio-Garcia JM, Gonzalez-Santos P. Asthma self-management education  
456 program by home monitoring of peak expiratory flow. *American journal of*  
457 *respiratory and critical care medicine*. 1995;151(2 Pt 1):353-9. doi:  
458 10.1164/ajrccm.151.2.7842191. PubMed PMID: 7842191.
- 459 20. Jennifer Y. So, Alejandra C. Lastra, Huaqing Zhao, Marchetti N, Criner GJ. Daily  
460 peak flow monitoring can be a useful tool in identifying COPD patients predisposed  
461 to worse outcomes. *Chronic Obstr Pulm Dis* 2016;3(1):398–405.
- 462 21. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al.  
463 COVID-19 pneumonia: different respiratory treatments for different phenotypes?  
464 *Intensive Care Med*. 2020. doi: 10.1007/s00134-020-06033-2.
- 465 22. Pilcher J, Ploen L, McKinstry S, Bardsley G, Chien J, Howard L, et al. A multicentre  
466 prospective observational study comparing arterial blood gas values to those obtained  
467 by pulse oximeters used in adult patients attending Australian and New Zealand  
468 hospitals. *BMC pulmonary medicine*. 2020;20(1):7. doi: 10.1186/s12890-019-1007-  
469 3. PubMed PMID: 31918697; PubMed Central PMCID: PMC6953261.
- 470 23. Shah S, Majmudar K, Stein A, Gupta N, Suppes S, Karamanis M, et al. Novel Use  
471 of Home Pulse Oximetry Monitoring in COVID-19 Patients Discharged From the  
472 Emergency Department Identifies Need for Hospitalization. *ACADEMIC*  
473 *EMERGENCY MEDICINE*. 2020;27:681–92. doi: 10.1111/acem.14053.
- 474 24. Hall JE. Guyton and hall textbook of medical physiology. 14. ed. pages cm p.
- 475 25. Leiner GC, Abramowitz S, Small MJ, Stenby VB, Lewis WA. Expiratory Peak Flow  
476 Rate. Standard Values for Normal Subjects. Use as a Clinical Test of Ventilatory

- 477 Function. *The American review of respiratory disease*. 1963;88:644-51. doi:  
478 10.1164/arrd.1963.88.5.644. PubMed PMID: 14082677.
- 479 26. Gerald LB, Tara FC. Peak expiratory flow monitoring in asthma2019 Accessed on  
480 November, 5, 2020. Available from: [https://www.uptodate.com/contents/peak-](https://www.uptodate.com/contents/peak-expiratory-flow-monitoring-in-asthma)  
481 [expiratory-flow-monitoring-in-asthma](https://www.uptodate.com/contents/peak-expiratory-flow-monitoring-in-asthma).
- 482 27. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in  
483 COVID-19. *The Journal of infection*. 2020;80(6):607-13. doi:  
484 10.1016/j.jinf.2020.03.037. PubMed PMID: 32283152; PubMed Central PMCID:  
485 PMC7194613.
- 486 28. O'Carroll O, MacCann R, O'Reilly A, Dunican EM, Feeney ER, Ryan S, et al.  
487 Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia.  
488 *The European respiratory journal*. 2020;56(2). doi: 10.1183/13993003.01492-2020.  
489 PubMed PMID: 32616588; PubMed Central PMCID: PMC7331654.
- 490 29. Bielecki M, Cramer GAG, Schlagenhauf P, Buehrer TW, Deuel JW. Body  
491 temperature screening to identify SARS-CoV-2 infected young adult travellers is  
492 ineffective. *Travel medicine and infectious disease*. 2020;37:101832. doi:  
493 10.1016/j.tmaid.2020.101832. PubMed PMID: 32763495; PubMed Central PMCID:  
494 PMC7403846.
- 495 30. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in  
496 COVID-19. *The American journal of emergency medicine*. 2020;38(7):1504-7. doi:  
497 10.1016/j.ajem.2020.04.048. PubMed PMID: 32317203; PubMed Central PMCID:  
498 PMC7165109.
- 499 31. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care.  
500 *Bmj*. 2020;368:m1182. doi: 10.1136/bmj.m1182. PubMed PMID: 32213507.
- 501 32. Altalag A, Road J, Wilcox P, Aboulhosn K. *Pulmonary Function Tests in Clinical*  
502 *Practice*. Switzerland: Springer Nature Switzerland AG; 2019.
- 503 33. Maiolo C, Mohamed EI, Fiorani CM, De Lorenzo A. Home telemonitoring for  
504 patients with severe respiratory illness: the Italian experience. *J Telemed Telecare*.  
505 2003;9(2):67-71. doi: 10.1258/135763303321327902. PubMed PMID: 12699574.
- 506 34. Graham LE, Zimmerman M, Vassallo DJ, Patterson V, Swinfen P, Swinfen R, et al.  
507 *Telemedicine--the way ahead for medicine in the developing world*. *Tropical doctor*.  
508 2003;33(1):36-8. doi: 10.1177/004947550303300118. PubMed PMID: 12568520.
- 509 35. Morlion B, Verbandt Y, Paiva M, Estenne M, Michils A, Sandron P, et al. A  
510 telemanagement system for home follow-up of respiratory patients. *IEEE Eng Med*  
511 *Biol Mag*. 1999;18(4):71-9. PubMed PMID: 10429904.
- 512 36. Pedone C, Chiurco D, Scarlata S, Incalzi RA. Efficacy of multiparametric  
513 telemonitoring on respiratory outcomes in elderly people with COPD: a randomized  
514 controlled trial. *BMC Health Serv Res*. 2013;13:82. doi: 10.1186/1472-6963-13-82.  
515 PubMed PMID: 23497109; PubMed Central PMCID: PMC3680224.

516  
517

## 518 **Figure Captions**

519

520 Figure 1: General architecture of the proposed system describing the home-based patient  
521 unit, which is set up around the patient to acquire data and the hospital unit, which enables  
522 the medical staff to telemonitor the patient's condition.

523

524 Figure 2: User interface in the cell phone application observed in the home unit. This  
525 application allows data transmission from the patient to the hospital. To make clinical use  
526 easier for non-technical personnel, a dedicated user-friendly front panel was developed.

527

528 Figure 3: User-friendly front panel that was developed to be used in the hospital  
529 environment. The program automatically downloads the patient's measurements and  
530 searches for abnormal values. The limits of abnormality may be adjusted by the user. In  
531 the presence of abnormal values, a red indicator light starts flashing, simultaneously with  
532 an alarm beep. More detail of this program may be obtained in the flow diagram presented  
533 in Figure 4, and the basic LabVIEW program described in Figure 5.

534

535 Figure 4: Flow diagram describing the basic operation of the program used in the hospital  
536 environment.

537

538 Figure 5: Basic LabVIEW program used in the hospital environment.

539

540 Figure 6: Home pulse oximetry values telemonitored during a 30-days period in controls  
541 (A) and in COVID-19-positive patients. (B). The red line describes the limit considered  
542 as a minimum normal value of saturation (92%). Three patients presented values below  
543 this limit.

544

545 Figure 7: Beats per minute (BPM) values telemonitored during a 30-days period in  
546 controls (A) and in COVID-19–positive patients (B). The red line describes the limit  
547 considered as a maximum normal value of BPM (100 BPM). Seven patients presented  
548 values above this limit along this home readings.

549

550 Figure 8: Median and 95% confidence intervals of the home monitored oxygen saturation  
551 (A) and BPM (B) in controls and COVID-19–positive patients.

552

553 Figure 9: Results obtained in the daily telemonitoring of temperature (A) and peak  
554 expiratory flow (C) in COVID-19–positive patients during 30 days. Box-plot descriptions  
555 of these results are also presented for the temperature (B) and peak expiratory flow (D).  
556 The top and the bottom of the box plot represent the 25th- to 75th-percentile values while  
557 the circle represents the mean value, and the bar across the box represents the 50th-  
558 percentile value.

559

Home-based patient unit

Internet

Analysis (hospital unit)




Figure 1




Figure 2



# Domiciliar monitoring of COVID-19

Number of Patients 16

Patient No 2

002jra

Name XXXXXXXXXXXXXXXXXXXX

SpO2 minimal (%) 92

Minimal measured SpO2 95

Inadequate saturation ●

BPM minimal for tachycardia 100

Maximal measured BPM 91

Tachycardia ●

## Analysis

Time interval in automatic scan (s)

10

Alarm control

OFF

Interval percentile



## Monitoring

Data acquisition Interval (min)

5



Interval percentile



Awaiting




Exit



Maximal temperature (degree C) 37,8

Maximal measured temperatura 37,7

Fever ●



Absolute Minimal EPF (%) Predicted EPF Minimal measured EPF  
Predicted 103,2 533 550 EPF ● ●




Figure 3




Figure 4




Figure 5





Figure 6







Figure 7



A



B

Figure 8




Figure 9




Figure S1